Themis Bioscience completes Series A Financing round – EUR 5 Million to advance promising vaccine candidates
18 May 2011 – Themis Bioscience GmbH, an Austrian start-up biotechnology company developing novel vaccines against emerging infectious diseases with high unmet medical need announced today the closing of a EUR 5 Million Series A Financing round co-led by the international venture capital funds Ventech and Crédit Agricole Private Equity.
moreR&D alliance with Institut Pasteur to fight tropical infectious diseases
14 September 2010 – Themis Bioscience GmbH, an Austrian start-up biotechnology company developing vaccines against tropical infectious diseases, announced today the formation of a joint R&D program with Institut Pasteur, the Paris based world leading research institution.
moreThemis Bioscience secures additional public funding
1 July 2010 – The Austrian Research Promotion Agency (FFG) supports the companys further development with EUR 1 Million
moreThemis Bioscience successfully closes seed-financing round - EUR 1 Million for company start-up
more- Series A Finance Round closed - 5 Mio. Euro for further product developmentmore
- Come and meet us! @ the Phacilitate Vaccine Forum, May 11-13, Barcelonamore
- R&D alliance with Institut Pasteur Themis and Institut Pasteur join forces to fight tropical infectious diseasesmore
- New Labs and Offices: Themis Bioscience moves to TZM Muthgassemore